KESIMPULAN DAN SARAN 7.1 Kesimpulan
Berdasarkan hasil penelitian tentang studi penggunaan albumin pada pasien PGK di Instalasi Rawat Inap Ilmu Penyakit Dalam RSUD Dr. Soetomo Surabaya dengan jumlah sampel 11 pasien, dapat diambil kesimpulan:
1. Capaian terapi albumin dilihat dari kadar albumin pre,
albumin post, dan kenaikan kadar albumin, serta kesesuaian pemberian dosis albumin berdasarkan perhitungan. Seluruh sampel penelitian mengalami kenaikan kadar albumin setelah diberikan terapi dengan kenaikan yang bervariasi tiap pasien. Rata-rata kenaikan kadar albumin sebesar 0,31±0,02 g/dL. Dari perhitungan kebutuhan albumin didapatkan 91,7% pasien telah diberikan dosis yang sesuai dengan dosis albumin yang dibutuhkan, sedangkan 8,3% pasien lainnya diberikan dosis albumin yang tidak sesuai dengan dosis yang dibutuhkan.
2. Faktor yang mempengaruhi kenaikan kadar albumin yaitu proteinuria, uremia, dan sintesis asam amino dalam tubuh. 3. Masalah terkait obat yang terjadi yaitu adanya indikasi
namun tidak diberikan terapi, sebesar 16,6%. 3.2 Saran
1. Perlu dilakukan pemeriksaan laboratorium sebelum dan sesudah pemberian albumin dengan interval waktu yang sama pada setiap pasien untuk mengetahui data aktual supaya hasil penelitian lebih representatif.
2. Perlu diperhatikan mengenai penyesuaian pemberian dosis pada pasien supaya efek terapi lebih mudah dicapai. 3. Perlu kolaborasi interprofesional yang melibatkan apoteker
dalam pemberian konseling, monitoring, evaluasi, dan tidak lanjut terkait penggunaan albumin untuk mendukung tercapainya outcome terapi yang diinginkan, termasuk durasi pemberian albumin, penyakit penyerta pasien, dan pemantauan terhadap penggunaan obat-obatan yang diberikan pada pasien.
DAFTAR PUSTAKA
Ackland, P., 2013. Prevalence, Detection, Evaluation and
Management of Chronic Kidney Disease. In: D.
Goldsmith, S. Jayawardene & P. Ackland, eds. ABC of
Kidney Disease. West Sussex: John Wiley & Sons, pp. 15-22.
Barrett, K. E., Barman, S. M., Scott, B. & Brooks, H. L., 2012. Renal
Physiology. In: Ganong's Review of Medical
Physiology. New York: McGraw Hill, pp. 674-680.
Boldt, J., 2010. Use of Albumin : an Update. British Journal of
Anaesthesia.
Callaghan, C., Shine, & Lasserson, D.S., 2011. Chronic Kidney
Disease: a large scale population-based study of the effects of introducing the CKD for eGFR reporting, p. 4.
Campbell, K., Bogard, J., & Millichamp, A., 2014. Nutrition
Prescription to Achieve Positive Outcome in Chronic Kidney Disease: A Systemic Review, pp. 417-419.
Cipolle, R.J., Strand, L.M., and Moley, P.C., 2004. Pharmaceutical
Care Practice: The Clinicians Guide, New York: McGraw-Hill Companies, Inc. pp.382-384
Cohen, S. D. & Kimmel, P. L., 2007. Nutritional Status, Psychological Issues and Survival in Hemodialysis
Patients. Contrib Nephrol, Volume 155, pp. 1-17.
Curhan, G.C., 2015. Nephrolithiasis. In: D.L. Longo, D.L. Kasper,
J.L. Jameson, A.S. Fauci, S.L. Hauser, and J. Loscalzo (Eds.). Harrison’s Principles of Internal Medicines, Ed.
Depkes RI, 1995. Farmakope Indonesia Edisi 4. Jakarta: Departemen Kesehatan. pp. 69-70.
Franch-Arcas, G., 2001. The Meaning of Hypoalbuminemia in
Clinical Practice. Clinical Nutrition, 20(3), pp. 265-269.
Gatta, A., Verardo, A. & Bolognesi, M., 2012. Hypoalbuminemia.
Intern Emerg Med, 7(3), pp. 193-199.
Greene R.J., Harris N.O., Goodyer L.I., 2000, Pathology and
Therapeutic for Pharmacist, A Basic for Clinical Pharmacy Practice, 2nd Edition, London : Pharmaceutical Press, p. 150-153, 176-179, 183-184. Guyton, A.C and Hall, J.E., 2006. Glomerular Filtration, Renal
Blood Flow, and Their Control. In : Guyton, A.C and
Hall, J.E. Textbook of Medical Phyisiology, Ed. 11th,
Philadelphia : Elsevier Saunders Inc., p. 307-311.
Hahn, G. R., 2011. Coloid Fluids. In: G. R. Hahn, ed. Critical Fluid
Therapy in The Perioperative Setting. New York: Cambridge University Press, pp. 11-16.
Hall, J. E., 2010. Guyton and Hall: Textbook of Medical
Physiology. 12th ed. New York: Saunders, pp. 413-416. Hasan, I. & Indra, T. A., 2008. Peran Albumin dalam
Penatalaksanaan Sirosis Hati. Medicinus, 21(2), p. 3.
Herrmann, F. R., Safran, C., Levkoff, S. E. & Minaker, K. L., 1992. Serum Albumin Level on Admission as a Predictor of
Death, Length of Stay, and Readmission. Arch Intern
Med, 152(1), pp. 125-130.
Hudson, J. Q. & Wazny, L. D., 2014. Chronic Kidney Disease. In: J.
Approach 9th Edition. New York: McGraw Hill, pp. 633-670.
Join Formulary Commitee, 2014. British National Formulary. 67
ed. London: Pharmaceutical Press., pp. 859-861.
Joy, M.S., 2005. Chronic Kidney Disease: Progression Modifying
Therapies. In : DiPiro J.T.,(Eds), Pharmacotheraphy A
Pathophysiologic Approach, 6th Edition, New York : The McGraw-Hill Companies, Inc, p. 799-820.
Kepmenkes RI, 2014. Riset Kesehatan Dasar, Jakarta: Kemenkes
RI.
Kementrian Kesehatan RI, 2011. Pedoman Intepretasi Data
Klinik. Jakarta: Kemenkes, pp. 3-7, 27-43.
Kidney Disease Outcome Quality Initiative Guidelines. 2007.
Definition and Classification of Stages of Chronic Kidney Disease, Part 4, Guideline 1, New york : National Kidney Foundation Inc., pp. 547-551, 568-569.
Konsensus Pengendalian dan Pencegahan Diabetes Mellitus tipe 2 di
Indonesia, 2011. Diabetes dengan Nefropati Diabetik,
Jakarta. pp. 56-57.
Krauss, A.G and Hak, L.J., 2000. Chronic Renal Disease. In :
Herfindal, E.T and Gourley, D.R. Textbook of
Therapeutic Drug and Disease Management, Ed. 7th, Vol. 1, Philadelphia : Lippincott Williams & Wilkins, p. 449-453, 463-472.
Mason, D.L., Assimon, M.M., 2013. Chronic Kidney Disease. In:
Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., Williams, B.R.
(Eds.). Applied Therapeutics: The Clinical Use of Drugs.
Ed, 10th, Philadelphia: Lippincott Williams&Wilkins, pp.
764-780.
McEvoy, G. M. et al., 2011. AHFS Drug Information Essentials.
Bethesda: American Society of Health-System Pharmacists.
McPhee, S. J. and Ganong, W. F., 2006. Renal Disease. Pathophysiology of Disease An Introduction to Clinical Medicines, Ed. 5th, New York: McGraw-Hill Companies, pp. 462-481.
National Kidney Foundation, 2005. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis
Patients. Chronic Kidney Disease, 45(4), pp. S1-S154.
Nitsch, D., 2013. Assosiations of estimated glomerular filtration rate and albuminuria with mortality and renal failure, pp. 3-4. Nolin, T.D., Himmelfarb, J., and Matzke, G.R., 2002. Drug Induced
Kidney Disease. In : DiPiro, J.T., Wells, B.G., and Posey,
L.M. Pharmacotherapy A Pathophysiology Approach,
Ed. 6th, New York : Mc Graw Hill Medical Publishing
Division, p.910.
Pagana, K. D. & Pagana, T. J., 2011. Mosby's Diagnostic and
Laboratory Test Reference. 11th ed. St. Louis: Elsevier., pp.352-354.
Perlman, R. L., Heung, M. & Ix, J. H., 2014. Renal Disease. Dalam: G. D. Hammer & S. J. McPhee, penyunt.
Clinical Medicine 7th Edition. New York: McGraw-Hill, pp. 455-481.
Peters, T., 1995. All About Albumin - Biochemistry, Genetics,
and Medical Applications. New York: Academic Press., pp. 12-13.
Rennke, H. G. & Denker, B. M., 2014. Renal Pathophysiology:
The Essentials. 4th ed. Philadelphia: Lippincott Williams & Wilkins., pp. 591-594.
Seifter, J.L., 2015. Urinary Tract Obstruction. In: D.L. Longo, D.L.
Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, and J.
Loscalzo (Eds.). Harrison’s Principles of Internal
Medicines, Ed. 19th, New York: McGraw-Hill Companies, pp. 1871-1876.
Shargel L, Pong SW, Yu ABC, 2005. Applied Biopharmaceutics &
Pharmakokinetics, 5th Edition, New York : The McGraw-Hill Companies, Inc, p. 134,673.
Soni, N., 2009. Human Albumin Solutions and the Controversy of
Crystalloids Versus Coloid. In: M. Contreras, ed. ABC of
Tranfusions. West Sussex: Wiley Blackwell, pp. 48-53. Sulistyoningrum, E., 2014. Perubahan Seluler dan Molekuler Pada
Nefropati Diabetik. Mandala of Health, Vol. 7 No. 1, hal. 514-520.
Wilson, Lorraine M., 2006. Gangguan Sistem Ginjal. In : Hartanto,
H., Susi, N., Wulansari, P., dan Mahanani, D.A.
Patofisiologi : Konsep Klinis Proses-Proses Penyakit,
Ed. 6, Vol. 2, Jakarta : EGC, Hal. 865; 917-918; 951-952; 964-965.
Wing, M. R., Raj, D. S. & Velasquez, M. T., 2015. Protein Energy Metabolism in Chronic Kidney Disease. Dalam: P. L.
Kimmel & M. E. Rosenberg, penyunt. Chronic Renal
Disease. Amsterdam: Academic Press, pp. 106-125. Yamagata, K., Ishida, K., Sairenchi, T., Takahashi, H., Ohba, S.,
Shiigai, T., Narita, M., Koyama, A., 2007. Risk Factors for Chronic Kidney Disease in a Community-based
Population: a 10-year follow-up study. Kidney
LAMPIRAN 2 SURAT KELAIKAN ETIK
LAMPIRAN 3 TERAPI LAIN
Pasien PGK pada penelitian ini juga menerima terapi lain selain albumin karena adanya berbagai kondisi yang menyertai. Berikut akan ditampilkan berbagai macam obat berdasarkan indikasi yang juga diterima pasien.
Nama obat Nama obat
Antihipertensi: Amlodipin Metildopa Analgesik narkotik: Codein Antibiotik: Ceftriakson Metronidazol Ciprofloxacin Meropenem Antihiperurisemia: Allopurinol Antidispepsia: Omeprazole Metoclopramide Sucralfat Ranitidin Resusitasi: PZ D5 NaCl Antikoagulan:
Kalnex (asam traneksamat) Vitamin K PRC Antipiretik: Paracetamol Diuretik: Furosemid
Suplemen & Terapi Penunjang:
Asam folat
Kalitake (Ca polystyrene sulfonate) KSR (Potassium chloride) Ca glukonas Kapsul garam Nabic Lain-lain: CaCO3 Nefrisol TKRPRG